TRDA - Entrada Therapeutics, Inc.
IEX Last Trade
17.59
0.055 0.313%
Share volume: 1,178
Last Updated: Thu 26 Dec 2024 08:30:10 PM CET
Research and Development in Biotechnology (except Nanobiotechnology):
-0.11%
PREVIOUS CLOSE
CHG
CHG%
$17.54
0.06
0.31%
Fundamental analysis
32%
Profitability
26%
Dept financing
12%
Liquidity
54%
Performance
38%
Performance
5 Days
0.57%
1 Month
-9.34%
3 Months
11.35%
6 Months
24.54%
1 Year
5.21%
2 Year
16.52%
Key data
Stock price
$17.59
DAY RANGE
$17.24 - $17.73
52 WEEK RANGE
$11.97 - $21.79
52 WEEK CHANGE
$7.01
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
11/14/2024
Company detail
CEO: Dipal Doshi
Region: US
Website: entradatx.com
Employees: 110
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Region: US
Website: entradatx.com
Employees: 110
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Entrada Therapeutics, Inc. develops endosomal escape vehicle (EEV) therapeutics for the treatment of multiple neuromuscular diseases. The company's lead product candidate is ENTR-601-44, which is in preclinical trail for Duchenne muscular dystrophy and myotonic dstrophy type 1.
Recent news